Predict your next investment

Agendia company logo
HEALTHCARE | Biotechnology
agendia.com

See what CB Insights has to offer

Founded Year

2003

Stage

Unattributed | Alive

Total Raised

$163.8M

Last Raised

$35M | 3 yrs ago

About Agendia

Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint FFPE as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient's individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.

Agendia Headquarter Location

Amsterdam, 1098 AX,

Netherlands

+31 (0)20 462 1500

Latest Agendia News

De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype

Jun 10, 2021

Harbeck, N. Abstract 503. Disclosures: Harbeck reports honoraria from, consultant/advisory roles with, research funding to her institution from, and/or stock and other ownership interests in Agendia, Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Genomic Health, Lilly, Merck Sharp & Dohme, Novartis, Odonate Therapeutics, Pfizer, Pierre Fabre, Roche, Roche/Genentech, Sandoz, Seattle Genetics, West German Study Group and Zodiac. Please see the abstract for all other researchers’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer. Researchers presented the first survival data from the randomized, phase 2 WSG-ADAPT-HR-/HER2+ trial — part of the ADAPT umbrella protocol — during the virtual ASCO Annual Meeting. Data were derived from Harbeck, N. Abstract 503. “For the first time, we have shown in a prospective multicenter trial both excellent pathologic complete response and survival in patients treated by de-escalated 12-week neoadjuvant weekly paclitaxel and dual HER2 blockade pertuzumab and trastuzumab, irrespective of additional chemotherapy use,” Nadia Harbeck, MD, PhD, head of the breast center, oncological therapy and clinical trials unit and chair for conservative oncology in the department of obstetrics and gynecology at University of Munich in Germany, said during her presentation. The study enrolled 134 patients with HER2-positive, hormone receptor-negative early breast cancer . Researchers randomly assigned patients 5:2 to trastuzumab (Herceptin, Genentech) plus pertuzumab (Perjeta, Genentech) alone or with paclitaxel. The trastuzumab-pertuzumab (n = 92) and trastuzumab-pertuzumab-paclitaxel (n = 42) groups had similar baseline characteristics, including median age (54 years vs. 51.5 years) and percentage of cT2 to cT4 tumors (59.8% vs. 61.9%). All patients received four cycles of trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and pertuzumab (840 mg loading dose followed by 420 mg/kg) every 3 weeks. Patients in the paclitaxel group also received 80 mg/m2 paclitaxel weekly for 12 weeks. Researchers obtained a biopsy of each patient before cycle 2 for early response assessment, Harbeck said. Pathologic complete response served as the primary endpoint; those who achieved this response after 12 weeks of study treatment could skip additional chemotherapy. The objective of the trial was to compare pathologic complete response in the paclitaxel group vs. the early responders in the pertuzumab-trastuzumab group. Investigators also assessed invasive DFS, distant DFS, OS and safety as secondary endpoints. Median follow-up was 59.9 months (range, 0.2-75.3). The trial ended early due to the superiority of pathologic complete response rates observed in the paclitaxel group (ypT0/is ypN0, 90.5% vs. 34.4%; ypT0 ypN0, 78.6% vs. 24.4%). Nadia Harbeck “We were pleasantly surprised by the 34% pathologic complete response rate after 12 weeks of dual HER2 blockade alone,” Harbeck told Healio. “Yet, I would like to point out that this kind of de-escalation with anti-HER2 therapy alone should currently only be done in clinical trials. Moreover, patients need to be carefully selected either upfront by HER2-enriched status, HER2 3+ or by early response to therapy after one to two cycles.” Seventy-nine percent of patients in the paclitaxel group had no further chemotherapy after achieving pathologic complete response, compared with 29% of patients in the dual HER2 blockade group. Harbeck described OS results as “excellent,” with only six events in the trial; 5-year OS rates were 98% in the paclitaxel group and 94% in the pertuzumab-trastuzumab-alone group (HR = 0.41; 95% CI, 0.05-3.55). Rates of invasive DFS at 5 years also favored the paclitaxel group (98% vs. 87%; HR = 0.32; 95% CI, 0.07-1.47), as did rates of distant DFS at 5 years (98% vs. 92%, HR = 0.34; 95% CI, 0.04-2.8). Early pathologic complete response after de-escalated therapy appeared associated with improved outcomes across the study and could be a predictive marker for further therapy de-escalation, Harbeck said. Patients with a pathologic complete response had a 5-year invasive DFS rate of 98% vs. 82% for those who did not have a pathologic complete response (HR = 0.14; 95% CI, 0.03-0.64). No pathologic complete responses occurred in the chemotherapy-free group among patients with low HER2 expression and/or basal-like disease subtype. Low HER2 expression and/or no early response appeared associated with worse DFS (P = 0.29) and a trend toward worse invasive DFS. Researchers observed no new safety signals. Investigators plan to provide data for the same treatment regimen in the WSG HER2+/HR+ TPII trial soon. “Our results are currently being validated by the ongoing COMPASS HER2 trial in the U.S. and DECRESCENDO in Europe,” Harbeck told Healio. “These trials will also answer the question for the optimal therapy for patients with no pathologic complete response after 12 [weeks of] paclitaxel plus dual blockade.” Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Agendia

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Agendia in 2 CB Insights research briefs, most recently on Dec 16, 2020.

Expert Collections containing Agendia

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Agendia is included in 6 Expert Collections, including Genomics.

G

Genomics

823 items

Companies involved in the capture, sequencing, and/or analysis of genetic data

W

Women's Health & Wellness

957 items

Startups focused on providing products and services catering to women's health and wellbeing.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

M

Medical Devices

10,917 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharmaceuticals

14,139 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Agendia Patents

Agendia has filed 11 patents.

The 3 most popular patent topics include:

  • Abdomen
  • Clusters of differentiation
  • DNA sequencing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/28/2015

9/11/2018

Experimental cancer drugs, Transcription factors, Breast cancer, Monoclonal antibodies for tumors, Oncology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/28/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/11/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Experimental cancer drugs, Transcription factors, Breast cancer, Monoclonal antibodies for tumors, Oncology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Agendia Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Agendia Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.